[Seite VIII↓]

7. Literaturverzeichnis

Pschyrembel Klinisches Wörterbuch. Melanom, malignes; Melanozyten. 259. Aufl., Walter de Gruyter Verlag Berlin - New York, 2002:1043-1046

Riede U-N, Schaefer H-E. Allgemeine und spezielle Pathologie. 4. Aufl., aktualisierter Nachdruck, Georg Thieme Verlag Stuttgart - New York, 2001:944-946.

Sebastian G, Stein A. Das maligne Melanom der Haut. UNI-MED Verlag, Bremen, 2000:11-126.

Reed RJ, Martin P: Variants of melanoma. Semin Cutan Med Surg. 1997;16:137-158.

Perniciaro C: Dermatopathological variants of malignant melanomas. Mayo Clin Proc. 1997;72:273-279.

Clark WH Jr, From L, Bernardino EA, et al.: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3): 705-727.

Jung EG. Dermatologie. 4. Aufl., Hippokrates Verlag, Stuttgart, 1998:228-238

Su WP: Malignant melanoma: basic approach to clinicopathologic correlation. Mayo Clin Proc. 1997;72(3):267-272.

Porras BH, Cockerell CJ: Cutaneous malignant melanoma: classification and clinical diagnosis. Semin Cutan Med Surg. 1997;16(2): 88-96.

Sahel JA, Albert DM: Intraocular melanomas. Cancer Treat Res. 1993;65:161-199.

Holman CDJ, Mulroney CD, Armstrong BK: Epidemiology of preinvasive and invasive malignant melanoma in Western Australia. Int J Cancer. 1980;25:317-323.

Robertson I, Cook MG, Dymock RB, Orell SR: Cutaneous malignant melanoma in South Australia. The main feature. Med J Australia. 1981;2:92-94.

Schreiber MM, Bozzo PD, Moon E: Malignant melanoma in Southern Arizona. Increasing incidence and sunlight as an etiolgic factor. Arch Dermatol. 1981;117:6-11.


[Seite innerhalb Literaturhinweis IX↓]

Little JH, Holt J, Davis N: Changing epidemiology of malignant melanoma in Queensland. Med J Australia. 1980;26(1): 66-69.

Rigel DS, Kopf AW, Friedman RJ: The rate of malignant melanoma in the United States: Are we making an impact? J Am Acad Dermatol. 1987;17(6):1050-1053.

Brobeil A, Rapaport D, Wells K et al: Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann Surg Oncol. 1997;4(1): 19-23.

Balch CM, Buzaid AC, Soong SJ et al: Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001;19(16):3635-3648.

Moehrle M, Blum A, Rassner G et al: Lymph node metastases of cutaneous melanoma: diagnosis by B-scan and color Doppler sonography. J Am Acad Dermatol. 1999;41(5): 703-709.

Zitelli JA, Brown CD, Hanusa BH: Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol. 1997;37(3): 422-429.

Orchard G, Wilson JE: Immunocytochemistry in the diagnosis of malignant melanoma. Br J Biomed Sci. 1994;51(1):44-56.

van der Bruggen P, Traversari C, Chomez P et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643-1647.

Cochran AJ, Wen DR, Herschman HR et al: Detection of S100 protein as an aid to the identification of melanocytic tumors. Int J Cancer. 1982;30:295-297.

Adema GJ, de-Boer AJ, Vogel AM et al: Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem. 1994;269:20126-20133.

Chen YT, Stockert E, Tsang S et al: Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci.1995;92:8125-8129.

Coulie PG, Brichard V, Van Pel A et al: A new gene coding for a differentiation antigen recognized by autologous cytolytic T-lymphocytes on HLA-A2 melanomas. J Exp Med. 1994;180(1): 35-42.


[Seite innerhalb Literaturhinweis X↓]

Gaugler B, Van den Eynde B, van der Bruggen P et al: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytoloytic T lymphocytes. J Exp Med. 1994;179(3):921-930.

Gown AM, Vogel AM, Hoak D et al: Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol. 1986;123:195-203.

Jungbluth AA, Busam KJ, Gerald WL et al: A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998;22:595-602.

Chen YT, Stockert E, Chen Y et al: Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc natl Acad Sci. 1994;91:1004-1008.

Kocher T, Schultz-Thater E, Gudat F et al: Identification and intracellular location of MAGE-3 gene product. Cancer Res. 1995;55(11):2236-2239.

Jungbluth AA, Iversen K, Coplan K et al: T311 - an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathol Res Pract. 2000;196:235-242.

Brasseur F, Rimoldi D, Lienard D et al: Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer. 1995;63(3):375-380.

Ordonez NG, Ji XL, Hickey RC: Comparison of HMB-45 monoclonal antibody and S100 protein in the immunhistochemical diagnosis of melanoma. Am J Clin Pathol. 1988;90:385-390.

Wick MR, Swanson PE, Rocamora A: Recognizion of malignant melanoma by monoclonal antibody HMB-45. An immunhistological study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol. 1988;15:201-207.

Esclamado RM, Gown AM, Vogel AM: Unique proteins defined by monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol. 1986;123:195-203.

Smoller BR, McNutt NS, Hsu A: HMB-45 recognizes stimulated melanocytes. J Cutan Pathol. 1989;16:49-53.


[Seite innerhalb Literaturhinweis XI↓]

Smoller BR, McNutt NS, Hsu A: HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma. Am J Pathol. 1989;13:680-684.

Sun J, Morton TH jr, Gown AM: Antibody HMB-45 identifies the cells of blue nevi. An immunhistochemical study on paraffin sections. Am J Surg Pathol. 1990;14:748-751.

Herrera GA, Hancock C: Specifity of antibody HMB-45. Arch Pathol Lab Med. 1992;116:900-901.

Argenyi ZB, Cain C, Bromley C et al: S100 protein-negative malignant melanoma: fact or fiction? A light-microscopic and immunohistochemical study. Am J Dermatopathol. 1994;16:233-240.

Gatter KC, Ralfkiaer E, Skinner J et al: An immunocytochemical study of malignant melanoma and its differential diagnosis from other malignant tumors. J Clin Pathol. 1985;38:1353-1357.

Hachisuka H, Sakamoto F, Nomura H etal: Immunohistochemical study of S100 protein and neuron specific enolase (NSE) in melanocytes and the related tumors. Acta Histochem. 1986;80:215-223.

Kindblom LG, Lodding P, Rosengren L et al: S100 protein in melanocytic tumors. An immunohistochemical investigation of benign and malignant melanocytic tumors and metastases of malignant melanoma and a characterization of the antigen in comparison to human brain.Acta Pathol Microbiol Immunol Scand. 1984;92:219-230.

Stefansson K, Wollmann RL, Moore BW et al: S100 protein in human chondrocytes. Nature. 1982;295:63-64.

Stefansson K, Wollmann RL, Moore BW: Distribution of S100 protein outside the central nervous system. Brain Res. 1982;234:309-317.

Tabuchi K, Moriya Y, Furuta T et al: S100 protein in human glial tumors. Qualitative and quantitative studies. Acta Neurochir Wien. 1982;65:239-251.

Vanstapel MJ, Gatter KC, de Wolf Peeters C et al: New sites of human S100 immunoreactivity detected with monoclonal antibodies. Am J Clin Pathol. 1986;85:160-168.


[Seite innerhalb Literaturhinweis XII↓]

Drier JK, Swanson PE, Cherwitz DL et al: S100 protein immunoreactivity in poorly differentiated carcinomas. Immunohistochemical comparison with malignant melanoma. Arch Pathol Lab Med. 1987;11:447-452.

Hofbauer GF, Kamarashev J, Geertsen R et al: Melan-A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res. 1998;84:337-343.

Kaufmann O, Koch S, Burghardt J et al: Tyrosinase, melan-A and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 1998;11(8):740-746.

Busam KJ, Chen YT, Old LJ et al: Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 1998;22:976-982.

Busam KL, Iversen K, Coplan KA et al: Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol. 1998;22(1):57-63.

Hofbauer GF, Kamarashev J, Geertsen R et al: Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol. 1998;25(4):204-209.

Basarab T, Picard JK, Simpson E et al: Melanoma antigen-encoding gene expression in melanocytic naevi and cutaneous malignant melanomas. Br J Dermatol. 1999;140(1):106-108.

Hofbauer GF, Schaefer C, Noppen C et al: MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastytic melanoma: frequency and distribution. Am J Pathol. 1997;151:1549-1553.

Gudat F, Zuber M, Durmuller U et al: The tumour associated antigen MAGE-1 is detectable in formalin-fixed paraffin sections of malignant melanoma. Virchows Arch. 1996;429:77-81.

Boenisch T (Hrsg.). Handbuch Immunchemische Färbemethoden. 3. Aufl., DakoCytomation Corporation, Carpinteria, DakoCytomation GmbH, Hamburg , 2003:5-79.


[Seite innerhalb Literaturhinweis XIII↓]

Shi SR, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991;39:741-748.

Guo Y, Ma J, Wang J et al: Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. Cancer Res. 1994;54:1561-1565.

Köhler G, Milstein C: Derivation of specific antibody producing tissue culture and tumor lines by cell fusion. Eur J Immunol. 1976;6:511-519.

Sternberger LA, Hardy PH Jr, Cuculis JJ et al: The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem. 1970;18:315-313.

Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.

Colombari R, Bonetti F, Zamboni G et al: Distribution of melanoma specific antibody (HMB-45) in benign and malignant melanocytic tumours. Virchows Archiv A Pathol Anat. 1988;413:17-24.

Mirecka J, Korabiowska M, Schauer A: Comparative distribution of S-100 protein and antigen HMB-45 in various types of melanomas and naevi. Pol J Pathol. 1995;46:167-172.

Shah IA, Gani OS, Wheler L: Comparative immunoreactivity of CD-68 and HMB-45 in malignant melanoma, neural tumors and nevi. Pathol Res Pact. 1997;193:497-502.

Swerdlow AJ, Storm HH, Sasieni PD: Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer. 1995;61:773-779.

Mottolese M, Venturo I, Benevolo M et al: Immunocytochemical diagnosis of amelanotic metastatic melanoma using monoclonal antibodies HMB-45 and Ep1-3. Melanoma Res. 1994;4:53-58.


[Seite innerhalb Literaturhinweis XIV↓]

Adema GJ,Boer AJ, Van’t Hullenaar R et al: Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol. 1993;143:1579-1585.

Cormier JN, Abati A, Fetsch P et al: Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother. 1998;21:27-31.

Fetsch PA, Riker AI, Marincola FM et al: Tyrosinase immunoreactivity in fine-needle aspiration samples of metastatic malignant melanoma. Cancer. 2000;90:252-257.

Jäger E, Ringhoffer M, Altmannsberger M et al: Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer. 1997;71:142-147.

Kageshita T, Kawakami Y, Hirai S et al: Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother. 1997;20:460-465.

Blessing K, Sanders DS, Grant JJ: Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology. 1998;32:139-146.

De Vries TJ, Fourkour A, Wobbes T et al: Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in humanmelanocytic lesions. Cancer Res. 1997;57:3223-3229.

Slingluff CL, Colella TA, Thompson L et al: Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunother. 2000;48:661-672.

De Vries TJ, Smeets M, de Graad R et al: Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol. 2001;193:13-20.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
22.10.2004